David M. Anderson, D.V.M.
Executive Director, Health Sciences Administration
B.A., Seattle University 1985
D.V.M., Washington State University 1989
P: 206-543-7202
F: 206-543-3473
E: danderso@uw.edu
About David Anderson
David M. Anderson is a laboratory animal veterinarian and pathologist who holds the position of Executive Director of Health Sciences Administration and Institutional Official for the University of Washington Animal Care and Use Program. Dr. Anderson’s current responsibilities as Executive Director for Health Science Administration provide opportunities for leadership across a broad scope of University research and operational activities. Health Science Administration provides administrative oversight and financial supervision for three interdisciplinary research Centers as well as departments with responsibility for animal use in research and education, environmental health and safety, facilities and academic support, risk management, student and staff health care, and strategic communications.
Research, Service & Training Interests
Dr. Anderson has directed a significant portion of his career towards biomedical research, specifically through development and implementation of animal models to address complex issues of human health and biology. As the former Director and Principal Investigator at the Washington National Primate Research Center, Dr. Anderson’s research focused on issues related to nonhuman primate models of AIDS with special emphasis on the neuropathology associated with the mechanisms of pathogenesis of the disease. Dr. Anderson previously served as attending veterinarian for nonhuman primates at the WaNPRC, providing multiple opportunities to serve as a resource and colleague for faculty, staff and post-doctoral fellows from the Department of Comparative Medicine.
Selected Publications
Hukkanen RR, Liggitt HD, Kelley ST, Grant R, Anderson DM, Hall RA, Tesh RB, Travassos DaRosa AP, Bielefeldt-Ohmann H. (2006). West Nile and St. Louis encephalitis virus antibody seroconversion, prevalence, and persistence in naturally infected pig-tailed macaques (Macaca nemestrina). Clin Vaccine Immunol. Jun;13(6):711-4.
Hukkanen RR, Liggitt HD, Kelley ST, Grant R, Anderson DM. (2006). Detection of systemic amyloidosis in the pig-tailed macaque (Macaca nemestrina). Comp Med. Apr;56(2):119-27.
Kinman LM, Worlein JM, Leigh J, Bielefeldt-Ohmann H, Anderson DM, Hu S-L, Morton WR, Anderson BD, Ho RJY (2004) HIV in central nervous system and behavioral development- an HIV-2 287 macaque model of AIDS. AIDS18(10):1363-1370.
Locher C, S.A. Witt, B.M. Ashlock, P. Polacino, S-L.Hu, S. Shiboski, A. M. Schmidt, M. B. Agy, D. M. Anderson, , S. Staprans, and J. A. Levy. (2004). Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine 22:2261-2272.
Doria-Rose NA, Ohlen C, Polacino P, Pierce CC, Hensel MT, Kuller L, Mulvania T, Anderson D, Greenberg PD, Hu S-L, Haigwood NL (2003) Multi-gene DNA prime-boost vaccines protect macaques from acute CD4+ T cell depletion after SHIV89.6P mucosal challenge. J Virol 77:11563-577.